Diagnosing Multiple Sclerosis (MS) can be very difficult and time consuming, sometimes taking months to years to receive a diagnosis.

Initially, physicians need to exclude other diseases that have similar symptoms. In addition, MRI examinations are not always clear and clinical symptoms are often inconclusive. These factors make diagnosing MS a complex and sometimes lengthy process, which can be very frustrating for individuals and physicians.

In order to help patients and physicians identify patients with a high probability of having MS, Glycominds has introduced the gMS^®Dx test, a new blood test for MS biomarkers. This revolutionary test helps physicians identify the patients who have had a first neurological event and a positive MRI that are likely to develop MS.

Why use the gMS^®Dx test?

•NEW - First blood based biomarker test validated for MS
•POWERFUL - High positive predictive value for identifying patients likely to have MS after the first neurological event
•The gMS^®Dx test differentiates MS from other neurological diseases
•SIMPLE - Easy, non-invasive test, that complements MRI